• Nathaniel P Katz, Joy Mou, Florence C Paillard, Barry Turnbull, Jeremiah Trudeau, and Malcolm Stoker.
• *Analgesic Solutions, Natick †LLX Solutions, Watertown ‡Biobridges, Wellesley, MA §Astellas Pharma Global Development, Leiderdorp, The Netherlands.
• Clin J Pain. 2015 Oct 1; 31 (10): 859-66.

ObjectivesQutenza is a high-dose capsaicin patch used to relieve neuropathic pain from postherpetic neuralgia (PHN) and HIV-associated neuropathy (HIV-AN). In clinical studies, some patients had a dramatic response to the capsaicin patch. Our objective was to determine the baseline characteristics of patients who best benefit from capsaicin patch treatment.MethodsWe conducted a meta-analysis of 6 completed randomized and controlled Qutenza studies by pooling individual patient data. Sustained response was defined as>50% decrease in the mean pain intensity from baseline to weeks 2 to 12, and Complete Response as an average pain intensity score≤1 during weeks 2 to 12. Logistic regression was used to identify predictors of response and Complete Response, and subgroups of patients who respond best to the capsaicin patch.ResultsBaseline pain intensity score (BPIS)≤4 was a predictor of Sustained and Complete Response in PHN and HIV-AN patients; absence of allodynia and presence of hypoesthesia, and a McGill Pain Questionnaire (MPQ) sensory score <22 were predictors of Sustained Response in PHN patients; female sex was a predictor of Sustained and Complete Response in HIV-AN patients. Thus, characteristics associated with the highest chance of responding to the capsaicin patch were, for PHN, BPIS≤4, MPQ sensory score≤22, absence of allodynia, and presence of hypoesthesia; for HIV-AN, they were female sex and BPIS≤4. Patients with these characteristics had a statistically significantly greater chance of responding to the capsaicin patch than other patients.DiscussionWe identified subpopulations of PHN and HIV-AN patients likely to benefit from the capsaicin patch.

26 keywords...

hide…